The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The expression level of HER3 ligand heregulin mRNA as a predictive biomarker for anti-HER3 antibody patritumab combined with erlotinib in non-small cell lung cancer.
Kimio Yonesaka
No relevant relationships to disclose
Hisato Kawakami
No relevant relationships to disclose
Hiroyasu Kaneda
No relevant relationships to disclose
Isamu Okamoto
No relevant relationships to disclose
Kenji Hirotani
Employment or Leadership Position - Daiichi Sankyo
Kazuto Nishio
No relevant relationships to disclose
Kazuhiko Nakagawa
No relevant relationships to disclose